• Dosed first patient in Phase 2 trial of OPNT002, nasal naltrexone, for AUD
  • Received additional BARDA funding for OPNT003, nasal nalmefene, development program
  • Announced positive Phase 2 pharmacokinetic (PK), safety and tolerability top-line results for multi-dose study of OPNT003, nasal nalmefene
  • Announced positive topline results from head-to-head pharmacodynamic study comparing OPNT003, nasal nalmefene, to 4mg nasal naloxone
  • Initiated rolling submission of New Drug Application to U.S. Food and Drug Administration for OPNT003 for the treatment of opioid overdose
  • Announced Notice of Allowance for U.S. patent with claims covering OPNT003 for the treatment of opioid overdose
  • Announced Notice of Allowance for U.S. Patent with claims covering OPNT004 for the treatment of cannabinoid hyperemesis syndrome